HK Stock Market Move | CLOUDBREAK-B(02592) further increased by over 10%, core product CBT-009 obtained patents in Japan and Europe.

Cloudbreak-B (02592) rose by over 10% again, with a cumulative increase of nearly 70% for the week. As of the time of writing, it rose by 8.82% to 7.9 Hong Kong dollars, with a trading volume of 6.2189 million Hong Kong dollars. On the news front, Bokang Vision Cloud announced that its fully owned subsidiary ADS USA has successfully obtained patents from the Japan Patent Office and the European Patent Office for one of the group's core products, CBT-009. It is expected that the group will be able to collaborate with large pharmaceutical companies to establish licensing arrangements for the production, development, and distribution of CBT-009 in Japan and Europe. CBT-009 is a new atropine eye preparation used to treat myopia in children and adolescents aged 5 to 19. In "Countdown to one month before the lock-up period ends, why is Cloudbreak-B (02592) experiencing a simultaneous increase in volume and price?" it is pointed out that on January 3, 2026, Cloudbreak Vision Cloud's two cornerstone investors will face the lifting of restrictions on their shares. Looking back, Cloudbreak Vision Cloud's stock price performance does not seem to be the result of intentional manipulation by the sponsor, but rather due to insufficient institutional capital leading to under-allocation in the national placement. The lackluster performance in the grey market and on the first day of trading may be due to anchor participants holding on to assets beyond expectations, ultimately leading to panic selling.